BGPartner advises on a USD 1.1 billion transaction

BGPartner advises on a USD 1.1 billion transaction - Araris Biotech to be acquired by Taiho Pharmaceutical 

Japan-based Taiho Pharmaceutical Co., Ltd. and Araris Biotech AG, a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), entered into a share purchase agreement pursuant to which Taiho Pharmaceutical will fully acquire Araris Biotech. The acquisition, expected to close in the first half of 2025, follows a research collaboration between the two companies that began in November 2023. Under the terms of the share purchase agreement, Taiho Pharmaceutical will pay USD 400 million at closing, with the potential for additional milestone payments of up to USD 740 million, as the company reaches unicorn status.

BGPartner, which has been advising Araris Biotech as Swiss legal counsel since its incorporation in 2019, advised Araris Biotech on all Swiss legal matters of this transaction. The team consisted of Oliver Gnehm (Partner), Thomas Gysin (Managing Associate) and Tessa Douma (Associate). Cooley LLP advised on all US legal matters.